This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1.JA Linder , Fluoroquinolone prescribing in the United States: 1995 to 2002. American Journal of Medicine 2005; 118: 259–268.
2.NX Chin , HC Neu . Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrobial Agents and Chemotherapy 1984; 25: 319–326.
3.JT Smith . Mutational resistance to 4-quinolone antibacterial agents. European Journal of Clinical Microbiology 1984; 3: 347–350.
4.W Cullmann , Comparative evaluation of recently developed quinolone compounds – with a note on the frequency of resistant mutants. Chemotherapy 1985; 31: 19–28.
6.FW Goldstein , JF Acar . Epidemiology of quinolone resistance: Europe and North and South America. Drugs 1995; 49: 36–42.
8.E Bouza , A European perspective on nosocomial urinary tract infections II. Report on incidence, clinical characteristics and outcome (ESGNI-004 study). European Study Group on Nosocomial Infection. Clinical Microbiology and Infection 2001; 7: 532–542.
9.KG Naber , Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. International Journal of Antimicrobial Agents 2008; 32: 145–153.
10.CE Smith , Assessment of the synergistic interactions of levofloxacin and ampicillin against Enterococcus faecium by the checkerboard agar dilution and time-kill methods. Diagnostic Microbiology and Infectious Diseases 1997; 27: 85–92.
11.D Landman , NK Mobarakai , JM Quale . Novel antibiotic regimens against Enterococcus faecium resistant to ampicillin, vancomycin, and gentamicin. Antimicrobial Agents and Chemotherapy 1993; 37: 1904–1908.
12.MS Whitman , Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium. Antimicrobial Agents and Chemotherapy 1993; 37: 2069–2073.
13.JS Garner , CDC definitions for nosocomial infections, 1988. American Journal of Infection Control 1988; 16: 128–140.
15.H MacAdam , Investigating the association between antibiotic use and antibiotic resistance: impact of different methods of categorising prior antibiotic use. International Journal of Antimicrobial Agents 2006; 28: 325–332.
16.LB Gasink , The categorization of prior antibiotic use: impact on the identification of risk factors for drug resistance in case control studies. American Journal of Infection Control 2007; 35: 638–642.
17.AD Harris , Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clinical Infectious Diseases 2001; 32: 1055–1061.
18.E Lautenbach , Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Archives of Internal Medicine 2002; 162: 2469–2477.
19.H Arslan , Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. Journal of Antimicrobial Agents and Chemotherapy 2005; 56: 914–918.
20.KM Killgore , KL March , BJ Guglielmo . Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Annals of Pharmacotherapy 2004; 38: 1148–1152.
22.SY Chen , Bacteremia in previously hospitalized patients: prolonged effect from previous hospitalization and risk factors for antimicrobial-resistant bacterial infections. Annals of Emergency Medicine 2008; 51: 639–646.
24.W Wilson , Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association rheumatic fever, endocarditis, and kawasaki disease committee, council on cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group. Circulation 2007; 116: 1736–1754.